Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study

BMC Cancer

Research Article

Angie Hui Ling Yeo¹  Han Kiat Ho¹  Maung Shwe¹  Ying Yun Lee¹  Jung-woo Chae²  Terence Ng²  Alexandre Chan³  Yan Xiang Gan⁴  Raymond C. H. Ng⁵  Chiea Chuen Khor⁶  Pat Pak Yan Chu⁷ 

[1] Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, 117543, Singapore, Singapore;Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, 117543, Singapore, Singapore;Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore;Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, 117543, Singapore, Singapore;Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore;Duke-NUS Medical School Singapore, Singapore, Singapore;Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore;Duke-NUS Medical School Singapore, Singapore, Singapore;Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore;Genome Institute of Singapore, Singapore, Singapore;Singapore Cord Blood Bank, K.K. Women’s and Children’s Hospital, Singapore, Singapore;

关键词: BDNF;    Breast cancer;    Cognition;    Genetics;    rs6265;   

DOI  :  10.1186/s12885-017-3861-9

 received in 2016-06-29, accepted in 2017-11-29,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundPreliminary evidence suggests that changes in plasma brain-derived neurotrophic factor (BDNF) levels may contribute to the occurrence of chemotherapy-associated cognitive impairment (CACI), and a previous study suggested that carriers of the BDNF Met homozygous genotype are protected from CACI.MethodsThis multicenter, prospective cohort study involved chemotherapy-receiving early-stage breast cancer (ESBC) patients. Self-perceived cognitive function was longitudinally assessed using the validated FACT-Cog (ver. 3) across three time points: Prior to chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy (T3). Plasma BDNF levels were quantified using enzyme-linked immunosorbent assay. Genotyping was performed using Sanger Sequencing.ResultsA total of 51 chemotherapy-receiving ESBC patients (mean age: 52.6 ± 9.5 years) were recruited, and 11 patients (21.6%) reported subjective cognitive impairment post-chemotherapy. Overall, there was a reduction in median plasma BDNF levels over time (T1: 5423.0 pg/ml; T2: 5313.6 pg/ml; T3: 4050.3 pg/ml; p < 0.01). After adjusting for confounding factors, longitudinal analysis revealed that BDNF levels were associated with self-reported concentration deficit (p = 0.032). Carriers of Val/Val (p = 0.011) and Val/Met (p = 0.003) BDNF genotypes demonstrated a significant reduction in plasma BDNF levels over time; however, plasma BDNF levels were similar across all time points among Met homozygous carriers (p = 0.107).ConclusionThere was a statistically significant change in BDNF levels post-chemotherapy in ESBC patients, and plasma BDNF levels were associated with self-perceived concentration deficit in patients receiving chemotherapy.

【 授权许可】

CC BY   
© The Author(s). 2017